FLT3 and acute myeloid leukemia: Relying on large scale mutational analysis in the genomic landscape, the treatment of AML improved significantly as the development of targeted therapies, such as targeting the FMS-like tyrosine kinase 3 (FLT3) and Isocitrate dehydrogenase (IDH) mutations, in the past several years (2).